Highly active antiretroviral therapy normalizes the potential for MIP-1 α production in HIV infection

Journal of Infection

Volumn 41, Issue 3, 2000, Pages 252-255

  Carter, L M ^a   Peters, B S ^a   Ellis, B A ^a   Wolstencroft, R A ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE; CHEMOKINE RECEPTOR CCR5; LAMIVUDINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; NELFINAVIR; RANTES; STAVUDINE;

ARTICLE; BLOOD CELL; BLOOD CULTURE; BLOOD DONOR; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MACROPHAGE;

EID: 0034526175     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1053/jinf.2000.0742     Document Type: Article

References (26)

1. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8 + T cells
2. CCR5: RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1
3. Identification of a major co-receptor for primary isolates of HIV-1
4. HIV-1 entry into CD4 + cells is mediated by the chemokine receptor CC-CKR-5
5. The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection
6. Serum chemokine levels in patients with non-progressing infection
7. Plasma levels of monocyte chemoattractant protein-1 but not those macrophage inhibitory protein-1 alpha and RANTES correlate with virus load in human immunodeficiency virus infection
8. Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils
9. C-C chemokines, pivotal in protection against HIV type 1 infection
10. Spontaneous and antigen-induced production of HIV-inhibitory beta-chemokines are associated with AIDS-free status
11. Change in circulating levels of the chemokines macrophage inflammatory proteins 1α and 1β, RANTES, monocyte chemotactic protein-1 and interleukin-16 following treatment of severely immunodeficient with indinavir
12. CCR5 and CXCR4 chemokine receptor expression and beta-chemokine production during early T cell repopulation induced by highly active anti-retroviral therapy
13. Sustained Suppression of plasma HIV RNA is associated with an increase in the production of mitogen-induced MIP-1 alpha and MIP-1 beta
14. Chemokine production in HIV-seropositive long-term asymptomatic individuals
15. Production of beta-chemokines in human immunodeficiency virus (HIV) infection: Evidence that high levels of macrophage inflammatory protein-1 beta are associated with a decreased risk of HIV disease progression
16. Chemokine receptors and chemokines in HIV infection
17. Antigen-specific release of β-chemokines by anti-HIV-1 cytotoxic T lymphocytes
18. β-chemokines are released from HIV-1-specific cytolytic T-cell granules complexed to proteoglycans
19. Distinctive calcineurin-dependent (FK506-sensitive) mechanism regulate the production of the CC chemokines macrophage inflammatory protein (MIP)-1 alpha, MIP-1 beta, and RANTES vs. IL-2 and TNF-alpha by activated human T cells
20. Chemokines and their role in cardiovascular diseases
21. CD8 + and CD45RA + human peripheral blood lymphocytes are potent sources of macrophage inflammatory protein 1α, interleukin-8 and RANTES
22. Endogenous production of β-chemokines by CD4 +, but not CD8 + T-cell clones correlated with the clinical state of human immunodeficiency virus type 1 (HIV-1)-infected individuals and may be responsible for blocking with non-syncytium-inducing HIV-1 in vitro
23. Alterations in the Immune Response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, Ritonavir
24. Preferential migration of activated CD4 + and CD8 + T cells in response to MIP-1α and MIP-1β
25. Cytotoxic l'lymphocytes, chemokines and antiviral immunity